{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:27:57Z","timestamp":1788834477218,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.urolonc.2022.07.018","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:28:01Z","timestamp":1663633681000},"page":"494.e1-494.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Cachexia index in predicting outcomes among patients receiving immune checkpoint inhibitor treatment for metastatic renal cell carcinoma"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5685-3748","authenticated-orcid":false,"given":"Volkan","family":"Aslan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9980-8397","authenticated-orcid":false,"given":"Atiye Cenay Karab\u00f6rk","family":"K\u0131l\u0131\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3835-2741","authenticated-orcid":false,"given":"Osman","family":"S\u00fctc\u00fco\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2497-5913","authenticated-orcid":false,"given":"Emrah","family":"Eraslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2150-8650","authenticated-orcid":false,"given":"Ahmet","family":"Bayrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2756-8646","authenticated-orcid":false,"given":"Berna","family":"\u00d6ks\u00fczo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2274-6586","authenticated-orcid":false,"given":"G\u00f6zde","family":"Tahtac\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9235-9592","authenticated-orcid":false,"given":"Nuriye","family":"\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3836-3854","authenticated-orcid":false,"given":"Aytu\u011f","family":"\u00dcner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3152-6008","authenticated-orcid":false,"given":"Nazan","family":"G\u00fcnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8731-9636","authenticated-orcid":false,"given":"Ahmet","family":"\u00d6zet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0038-3569","authenticated-orcid":false,"given":"Ozan","family":"Yaz\u0131c\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.urolonc.2022.07.018_bib0001","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3390\/cancers13020231","article-title":"Tumor microenvironment features as predictive biomarkers of response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC)","volume":"13","author":"Simonaggio","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.urolonc.2022.07.018_bib0002","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/bjc.2011.189","article-title":"The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis","volume":"105","author":"Gooden","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2022.07.018_bib0003","doi-asserted-by":"crossref","first-page":"S1157","DOI":"10.1016\/j.annonc.2020.08.2254","article-title":"LBA25 Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in na\u00efve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial","volume":"31","author":"Vano","year":"2020","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.urolonc.2022.07.018_bib0004","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.3390\/cancers12092662","article-title":"Predicting response to immunotherapy in metastatic renal cell carcinoma","volume":"12","author":"Tucker","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.urolonc.2022.07.018_bib0005","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.juro.2015.08.071","article-title":"Prognostic significance of sarcopenia in patients with metastatic renal cell carcinoma","volume":"195","author":"Fukushima","year":"2016","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2022.07.018_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100095","article-title":"Body composition as a modulator of response to immunotherapy in lung cancer: time to deal with it","volume":"6","author":"Trestini","year":"2021","journal-title":"ESMO open"},{"issue":"1","key":"10.1016\/j.urolonc.2022.07.018_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2891-9-69","article-title":"Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature","volume":"9","author":"Gupta","year":"2010","journal-title":"Nutr J"},{"issue":"CMO","key":"10.1016\/j.urolonc.2022.07.018_bib0008","doi-asserted-by":"crossref","first-page":"S30891","DOI":"10.4137\/CMO.S30891","article-title":"Cachexia index in advanced non-small-cell lung cancer patients","volume":"9","author":"Jafri","year":"2015","journal-title":"Clin Med Insights Oncol"},{"key":"10.1016\/j.urolonc.2022.07.018_bib0009","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.nut.2018.08.001","article-title":"Body composition evaluation with computed tomography: contrast media and slice thickness cause methodological errors","volume":"59","author":"Morsbach","year":"2019","journal-title":"Nutrition"},{"issue":"3","key":"10.1016\/j.urolonc.2022.07.018_bib0010","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3390\/cells9030561","article-title":"Myeloid-derived suppressor cells as a therapeutic target for cancer","volume":"9","author":"Law","year":"2020","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.urolonc.2022.07.018_bib0011","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ctrv.2013.11.007","article-title":"Towards a simple objective framework for the investigation and treatment of cancer cachexia: the Glasgow Prognostic Score","volume":"40","author":"Douglas","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.urolonc.2022.07.018_bib0012","first-page":"188","article-title":"Association between an inflammatory-nutritional index and nutritional status in cancer patients","volume":"28","author":"Pastore","year":"2013","journal-title":"Nutr Hosp"},{"issue":"4","key":"10.1016\/j.urolonc.2022.07.018_bib0013","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3747\/co.v17i4.567","article-title":"The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer","volume":"17","author":"Kasymjanova","year":"2010","journal-title":"Curr Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2022.07.018_bib0014","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1038\/bjc.2013.515","article-title":"Montreal prognostic score: estimating survival of patients with non-small cell lung cancer using clinical biomarkers","volume":"109","author":"Gagnon","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2022.07.018_bib0015","series-title":"Seminars in cancer biology","article-title":"Cancer-related inflammation: common themes and therapeutic opportunities","year":"2012"},{"key":"10.1016\/j.urolonc.2022.07.018_bib0016","series-title":"Urologic Oncology: Seminars and Original Investigations","article-title":"The prognostic value of the neutrophil-lymphocyte ratio in renal oncology: A review","year":"2017"},{"issue":"1","key":"10.1016\/j.urolonc.2022.07.018_bib0017","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cncr.31778","article-title":"The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy","volume":"125","author":"Bilen","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2022.07.018_bib0018","series-title":"Urologic Oncology: Seminars and Original Investigations","article-title":"Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma","year":"2015"},{"issue":"1","key":"10.1016\/j.urolonc.2022.07.018_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-39120-6","article-title":"Impact of sarcopenia in patients with advanced non\u2013small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study","volume":"9","author":"Shiroyama","year":"2019","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.urolonc.2022.07.018_bib0020","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/bjc.2016.431","article-title":"The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma","volume":"116","author":"Daly","year":"2017","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.urolonc.2022.07.018_bib0021","first-page":"2075","article-title":"Sarcopenia and inflammation are independent predictors of survival in male patients newly diagnosed with small cell lung cancer","volume":"24","author":"Go","year":"2016","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2022.07.018_bib0022","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1634\/theoncologist.2019-0751","article-title":"Combined effect of sarcopenia and systemic inflammation on survival in patients with advanced stage cancer treated with immunotherapy","volume":"25","author":"Bilen","year":"2020","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.urolonc.2022.07.018_bib0023","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.09.001","article-title":"High neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are associated with symptomatic internal carotid artery stenosis","volume":"28","author":"Massiot","year":"2019","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.urolonc.2022.07.018_bib0024","first-page":"2689","article-title":"Body composition variables as radiographic biomarkers of clinical outcomes in metastatic renal cell carcinoma patients receiving immune checkpoint inhibitors","author":"Martini","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2022.07.018_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0425-8","article-title":"Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab","volume":"6","author":"Zahoor","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2022.07.018_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0315-0","article-title":"Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma","volume":"6","author":"Lalani","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.urolonc.2022.07.018_bib0027","doi-asserted-by":"crossref","unstructured":"Tucker, MD., Brown, LC, Kao, C, Hirshman, N, Kinsey, EN, Chen, YW, et al. (2021). Association of baseline neutrophil-to-eosinophil ratio (NER) and neutrophil-to-lymphocyte ratio (NLR) with response to combination immunotherapy (IO) with ipilimumab plus nivolumab (ipi\/nivo) in patients with metastatic renal cell carcinoma (mRCC).","DOI":"10.1200\/JCO.2021.39.15_suppl.4563"},{"key":"10.1016\/j.urolonc.2022.07.018_bib0028","doi-asserted-by":"crossref","unstructured":"Bilen MA, Rini BI, Voss MH, Larkin J, Haanen JB, Albiges L. et al. Association of neutrophil-to-lymphocyte ratio with efficacy of first-line avelumab plus axitinib vs. sunitinib in patients with advanced renal cell carcinoma enrolled in the phase 3 JAVELIN renal 101 trial. Clinical Cancer Research 2021.","DOI":"10.1158\/1078-0432.CCR-21-1688"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922002782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922002782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:25:36Z","timestamp":1761042336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143922002782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1078143922002782"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.07.018","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cachexia index in predicting outcomes among patients receiving immune checkpoint inhibitor treatment for metastatic renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}